Tositumomab, PMID: 31643663
I-131 tositumomab, PMID: 20590521
Tositumomab I 131, PMID: 29999771
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma, PMID: 15653661
131 I-Tositumomab, PMID: 20641455
Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma, PMID: 14748653
131I tositumomab, PMID: 18034570
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab, PMID: 12728404
Tositumomab and iodine I 131 tositumomab (Bexaar), PMID: 21436340
The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab, PMID: 12728405
Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma, PMID: 17547519
A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma, PMID: 15934835
Targeted Radionuclide Therapy: A Historical and Personal Review, PMID: 31843064
Tositumomab and iodine [131I] tositumomab in the management of follicular lymphoma. An oncologist's view, PMID: 15640794
Iodine-131 tositumomab (Bexxar) in a radiation oncology environment, PMID: 16979436
Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab, PMID: 21386787
I-Tositumomab in lymphoma, PMID: 19862360
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies, PMID: 28918995
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma, PMID: 27798787
Development of 131I-tositumomab, PMID: 15786026
131I-tositumomab therapy as initial treatment for follicular lymphoma, PMID: 15689582
Radioimmunotherapy with tositumomab and iodine-131 tositumomab for low-grade non-Hodgkin lymphoma: nursing implications, PMID: 15547634
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab, PMID: 17530015
Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members, PMID: 11779293
Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab, PMID: 12899647
Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19, PMID: 33131530
Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice, PMID: 17942813
Observational Retrospective Study of Altered Biodistribution of Tositumomab and 131I-Tositumomab, PMID: 26338897
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab, PMID: 15613695
Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma, PMID: 32800518
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study, PMID: 20458031
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement, PMID: 17325895
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas, PMID: 16186600
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma, PMID: 32243637
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911, PMID: 16896003
The radioisotope contributes significantly to the activity of radioimmunotherapy, PMID: 15585610
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes, PMID: 22955187
Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin's lymphoma, PMID: 19707321
A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy, PMID: 11884495
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas, PMID: 11579112
131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling, PMID: 20554734
CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma, PMID: 26832194
Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma, PMID: 15084620
Cancer immunotherapy, PMID: 21355777
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma, PMID: 16110029
131I tositumomab: a viewpoint by Michael L. Grossbard, PMID: 18034571
The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab, PMID: 25383420
131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma, PMID: 19543946
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab, PMID: 16204016
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab, PMID: 15731177
Assessing the Clinical Effectiveness of Radioimmunotherapy with Combined Radionuclide/Monoclonal Antibody Conjugates in Cancer Treatment: Insights from Randomised Clinical Trials., PMID:40361339
Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin's lymphoma., PMID:38464386
A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma., PMID:38207010
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma., PMID:37379264
Theranostics in Hematooncology., PMID:37290799
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update., PMID:36635112
Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis., PMID:36470547
Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using 213Bi-Anti-CD20 Monoclonal Antibody., PMID:35981897
Immunotherapy in indolent Non-Hodgkin's Lymphoma., PMID:35663281
Construction of miRNA-regulated drug-pathway network to screen drug repurposing candidates for multiple sclerosis., PMID:35356949
Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas., PMID:35158894
Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting., PMID:34996594
Perspectives on metals-based radioimmunotherapy (RIT): moving forward., PMID:33995659
Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go., PMID:33900820
Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis., PMID:33547368
Network meta-analysis of targeted therapies for diffuse large B cell lymphoma., PMID:33308179
Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19., PMID:33131530
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma., PMID:32243637
Targeted Radionuclide Therapy: A Historical and Personal Review., PMID:31843064
Radioimmunotherapy in Non-Hodgkin's Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar., PMID:31546999
Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma., PMID:32800518
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study., PMID:29396094
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016., PMID:29356608
Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts., PMID:29348316
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies., PMID:28918995
Shifting Focus in the Therapeutics of Immunobullous Disease., PMID:28584371
Whither Radioimmunotherapy: To Be or Not To Be?, PMID:28428282
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma., PMID:27798787
A pioneer experience in Malaysia on In-house Radio-labelling of (131)I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose (131)I-rituximab-BEAM conditioning autologous transplant., PMID:27472826
Emerging antibodies for the treatment of multiple myeloma., PMID:27195659
Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma., PMID:27130328
Safety and efficacy of radioimmunotherapy (RIT) in treatment of non-Hodgkin's lymphoma in the community setting., PMID:27067042
Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma., PMID:26897716
CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma., PMID:26832194
[Ceramide participates in cell programmed death induced by Type II anti-CD20 mAb]., PMID:26739069
Long-term follow-up of previously treated and treatment-naïve patients who received tositumomab and I-131 tositumomab., PMID:26696131
Observational Retrospective Study of Altered Biodistribution of Tositumomab and 131I-Tositumomab., PMID:26338897
Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity., PMID:26257518
Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission., PMID:26133724
Factors affecting the stability and repeatability of gamma camera calibration for quantitative imaging applications based on a retrospective review of clinical data., PMID:26116127
Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies., PMID:25823738
Marrow hypoplasia: a rare complication of untreated Grave's disease., PMID:25627052
Type II anti-CD20 mAb-induced lysosome mediated cell death is mediated through a ceramide-dependent pathway., PMID:25603047
Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain., PMID:25568316
Radioimmunoconjugates for the treatment of cancer., PMID:25440606
Ceramide participates in lysosome-mediated cell death induced by type II anti-CD20 monoclonal antibodies., PMID:25393677
The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab., PMID:25383420
Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies., PMID:25379535
For research use only. Not for human or drug use.
